Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Confirmatory study of ISN001 for epidermolysis bullosa skin ulcers
jRCT2033210128Completed
- Sponsor
- Ishin Pharma
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of sucralfate in epidermolysis bullosa (EB), dystrophic epidermolysis bullosa (DEB), junctional epidermolysis bullosa (JEB) and 1 more, sponsored by Ishin Pharma. Primary endpoints: Average rate of change in skin ulcer lesion area during evaluation period 1 and Average rate of change in skin ulcer lesion area during evaluation period 2. Started May 2021; status: completed.
02
Drugs
sucralfate
03
Conditions
epidermolysis bullosa (EB)dystrophic epidermolysis bullosa (DEB)junctional epidermolysis bullosa (JEB)epidermolysis bullosa simplex (EBS)
Beyond the preview
Go deeper on jRCT2033210128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033210128.